Advanced Life Sciences Holdings Inc
Advanced Life Sciences — UBS Global Life Sciences Conference 2008
22 slides from Advanced Life Sciences's conference presentation, Sep 24, 2008
Slide 1: UBS Global Life Sciences Conference
NASDAQ: ADLS UBS Global Life Sciences Conference September 24, 2008 ADVANCED LIFE SCIENCESTM Advancing Discoveries For Health
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains forward-looking statements about Advanced Life Sciences Holdings, Inc., including statements regarding the clinical trials and regulatory pathway of cethromycin. Forward-looking statements represent our management’s judgment regarding future events.
Slide 3: Clinical Pipeline
Anti-melanoma drug Enrolling Phase I/II clinical trial Broad biodefense countermeasure DOD contract for multiple indications Novel respiratory antibiotic NDA submission planned in Q3 Clinical Pipeline ALS-357 Cethromycin Cethromycin
Slide 4: Investment Highlights
4 Investment Highlights Pre-commercial stage biopharma developing cethromycin for respiratory tract infections Cethromycin designed to overcome bacterial resistance in the community NDA submission planned in Q3 for cethromycin in community acquired pneumonia (CAP) Additional downstream indications f
Slide 5: Macrolides and Penicillins are Losing Effectiveness
5 Macrolides and Penicillins are Losing Effectiveness Resistance is driving demand for new RTI therapies 0 10 20 30 40 50 60 70 80 90 100 1990 1995 2000 2005 S. Pneumoniae: Pen-R S. Pneumoniae: Mac-R Donald E. Low; Industry Analysis, Antimicrobial Resistance, Mt. Sinai Hospital & University of Toron
Slide 6: Fluoroquinolones Causing Collateral Damage
6 Fluoroquinolones Causing Collateral Damage Overuse of fluoroquinolones has caused... – Increased incidence of Clostridium difficile associated disease (CDAD) and class cross resistance • Cethromycin kills C. difficile toxin producing strains and protects against CDAD – New black box warning for te
Slide 7: Growing Demand for Antibiotics to Overcome Resistance
7 Growing Demand for Antibiotics to Overcome Resistance Without Causing Collateral Damage Resistance in RTIs is a $5 billion economic burden in the U.S.1 Cost of hospitalized CAP patient failing penicillins or macrolides is $15,000 vs. $200 office visit with prescription2 Economic burden for CDAD is
Slide 8: Cethromycin – Novel Respiratory Antibiotic
8 Cethromycin – Novel Respiratory Antibiotic Novel once-a-day oral antibiotic tested in nearly 5,200 subjects demonstrating strong potency and favorable safety profile Active against broad range of respiratory tract pathogens Designed to overcome penicillin and macrolide resistance Active against fl
Slide 9: U.S. Adult Oral Antibiotic Market Share
9 Macrolides 24% Other 16% Quinolones 17% Penicillins 43% U.S. Adult Oral Antibiotic Market Share 220 Million Prescriptions Total Market is $7 Billion* * IMS Data Resistance and collateral damage driving demand for new therapies
Slide 10: Cethromycin – U.S. RTI Market Potential
10 Cethromycin – U.S. RTI Market Potential CAP affects 6 million patients each year with 10 million physician visits Bronchitis affects 13 million patients per year Sinusitis impacts 31 million patients annually, with 25 million office visits Pediatric RTI market represents 50 million annual prescri
Slide 11: Cethromycin – Potential CAP Treatment
11 Cethromycin – Potential CAP Treatment CAP is gold standard for RTI and the 6th leading cause of death in the U.S. 6 million cases of CAP annually in the U.S. with annual spend of $2 billion for antibiotics Clearer regulatory pathway to approval in CAP Potent activity against Streptococcus pneumon
Slide 12: Downstream Indications for Cethromycin
Downstream Indications for Cethromycin Moderate-to-Severe CAP, CA-MRSA pneumonia IV formulation for hospital CAP and IV-to-pill “switch” Bronchitis, pharyngitis and sinusitis Pediatric formulation for respiratory infections including CAP and otitis media Biodefense applications Narrowing competitive
Slide 13: Spotlight on Emerging CA-MRSA Challenge
Spotlight on Emerging CA-MRSA Challenge Cethromycin demonstrated excellent in vitro activity against CA-MRSA clinical isolates (USA300 clone). Cethromycin was highly active against 100% of the 170 isolates tested showing MIC90 value of < 0.002 micrograms/mL 99.4% of these USA300 isolates were interm
Slide 14: Cethromycin – Biodefense Applications
14 Cethromycin – Biodefense Applications Need novel agents with new mechanisms for bioterrorism protection Superior potency in vitro vs. approved drugs against more than 30 anthrax strains and other high-priority pathogens Shown to be 100% protective for prophylactic treatment of inhalation anthrax
Slide 15: Global Commercialization Strategy
15 Global Commercialization Strategy Assuming FDA approval, launch in CAP with commercial partners Worldwide rights (ex-Japan) With commercial partners, co-develop cethromycin for other indications; option to co-promote downstream Expect milestone and royalty based deal structure Negotiations underw
Slide 16: Milestones Achieved To Date
16 Milestones Achieved To Date Reported positive data for cethromycin in two pivotal phase III trials in CAP Favorable cardiac safety demonstrated in thorough QT study Formed National Advisory Board of physician experts to support NDA and commercialization processes Established manufacturing partner
Slide 17: Oncology Program
Oncology Program Anti-melanoma drug Enrolling Phase I/II clinical trial ALS-357
Slide 18: ALS-357
ALS-357 54,000 new melanoma cases per year; no effective therapies Orphan Drug status granted by FDA Unique mechanism: induces mitochondria-mediated apoptosis Strong in vivo safety; 85% tumor regression Enrolling Phase I/II clinical trial O OH HO H H H H
Slide 19: Near-term Milestones
19 Near-term Milestones NDA submission for CAP Commercial partnerships Key Value Drivers Conference call update morning of October 1st
Slide 20: Corporate Information
20 Corporate Information Beneficial Holder Percent Ownership Common Stock (Fully Diluted) Management 19% Abbott Laboratories 3% Institutions 78% TOTAL 100% Market Nasdaq Ticker ADLS Cash Balance (6/30/08) $9.1M Shares Outstanding (fully diluted) 50.6M Share Price Range (52-week) $0.67-$2.85 Average
Slide 21: Investment Highlights
21 Investment Highlights Pre-commercial stage biopharma developing cethromycin for respiratory tract infections Cethromycin designed to overcome bacterial resistance in the community NDA submission planned in Q3 for cethromycin in community acquired pneumonia (CAP) Additional downstream indications
Slide 22: Thank you
4 | € ADVANCED IFE SCIENCES” x Advancing Discoveries For Health NASDAQ: ADLS > Thank you %
Advanced Life Sciences Holdings — UBS Global Life Sciences Conference 2008 on 6ix